G
George L. Drusano
Researcher at University of Maryland, Baltimore
Publications - 59
Citations - 2911
George L. Drusano is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Population & Imipenem. The author has an hindex of 32, co-authored 59 publications receiving 2809 citations. Previous affiliations of George L. Drusano include Miles College & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection : Clinical Implications of an Extended-Infusion Dosing Strategy
TL;DR: It is suggested that improved outcomes may be realized by administering extended-infusion piperacillin-tazobactam therapy to critically ill patients with P. aeruginosa infection.
Journal ArticleDOI
Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial
Samir G. Sakka,Anna K. Glauner,Jürgen B. Bulitta,Martina Kinzig-Schippers,Wolfgang Pfister,George L. Drusano,Fritz Sörgel +6 more
TL;DR: This study studied 20 critically ill patients with nosocomial pneumonia and investigated whether continuous infusion with a reduced total dose, compared to the standard regimen of intermittent short-term infusion, results in a superior probability of target attainment as assessed by the fT>MIC value of imipenem.
Journal ArticleDOI
The Relationship between Quinolone Exposures and Resistance Amplification Is Characterized by an Inverted U: a New Paradigm for Optimizing Pharmacodynamics To Counterselect Resistance
TL;DR: An “inverted-U” relationship was identified wherein resistant subpopulations rose initially and then declined with increasing exposure, until reaching a threshold that prevented resistance amplifications.
Journal ArticleDOI
Absolute oral bioavailability of ciprofloxacin.
TL;DR: It is concluded that ciprofloxacin is rapidly absorbed and reliably bioavailable in these healthy volunteers and should be undertaken in target patient populations under actual clinical circumstances.
Journal ArticleDOI
Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing
William W. Hope,Nita L. Seibel,Cindy L. Schwartz,Antonio Arrieta,Patricia M. Flynn,Aziza T. Shad,Edythe A. Albano,James Keirns,Donald N. Buell,Tawanda Gumbo,George L. Drusano,Thomas J. Walsh +11 more
TL;DR: The allometric power model developed in this study enables identification of pediatric dosage regimens of micafungin which, based upon Monte Carlo simulations, result in equivalent drug exposures to those observed in adults, for which antifungal efficacy has been established.